Allergan Stock Price, Forecast & Analysis (NYSE:AGN)

Allergan trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGN."

Allergan declared a quarterly dividend on Friday, October 25th. Investors of record on Wednesday, November 13th will be paid a dividend of $0.74 per share on Friday, December 13th. This represents a $2.96 dividend on an annualized basis and a dividend yield of 1.60%. The ex-dividend date is Tuesday, November 12th. View Allergan's Dividend History.

Allergan declared that its board has initiated a stock buyback program on Tuesday, January 29th 2019, which permits the company to buyback $2,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to reacquire up to 4.1% of its stock through open market purchases. Stock buyback programs are typically a sign that the company's leadership believes its shares are undervalued.

Allergan plc (NYSE:AGN) released its earnings results on Tuesday, November, 5th. The company reported $4.25 EPS for the quarter, hitting the consensus estimate of $4.25. The business had revenue of $4.03 billion for the quarter, compared to the consensus estimate of $3.88 billion. Allergan had a positive return on equity of 9.08% and a negative net margin of 58.50%. The company's revenue for the quarter was up 2.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $4.25 EPS. View Allergan's Earnings History.

Allergan is scheduled to release their next quarterly earnings announcement on Tuesday, February 4th 2020. View Earnings Estimates for Allergan.

Allergan issued an update on its FY19 earnings guidance on Tuesday, November, 5th. The company provided EPS guidance of >$16.55 for the period, compared to the Thomson Reuters consensus EPS estimate of $16.74. The company issued revenue guidance of $15.6-15.8 billion, compared to the consensus revenue estimate of $15.58 billion.

20 brokers have issued 1-year target prices for Allergan's shares. Their forecasts range from $144.95 to $203.00. On average, they anticipate Allergan's stock price to reach $175.90 in the next twelve months. This suggests that the stock has a possible downside of 4.9%. View Analyst Price Targets for Allergan.

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allergan in the last year. There are currently 16 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Allergan.

Media stories about AGN stock have been trending positive recently, according to InfoTrie. InfoTrie rates the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Allergan earned a media sentiment score of 3.0 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for Allergan.

Allergan saw a increase in short interest during the month of October. As of October 15th, there was short interest totalling 11,450,000 shares, an increase of 10.8% from the September 15th total of 10,330,000 shares. Based on an average daily trading volume, of 3,220,000 shares, the days-to-cover ratio is presently 3.6 days. Approximately 3.5% of the shares of the company are short sold. View Allergan's Current Options Chain.

Some companies that are related to Allergan include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Mylan (MYL), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Horizon Therapeutics (HZNP), The Medicines (MDCO), Nektar Therapeutics (NKTR), Zogenix (ZGNX) and Corcept Therapeutics (CORT).

Based on aggregate information from My MarketBeat watchlists, some companies that other Allergan investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Micron Technology (MU), Aegean Marine Petroleum Network (ANW), NIC (EGOV), Transocean (RIG) and United Rentals (URI).

Allergan's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.54%), Newport Trust Co (0.38%), California Public Employees Retirement System (0.24%), Diamond Hill Capital Management Inc. (0.20%), Strs Ohio (0.20%) and Rhumbline Advisers (0.15%). Company insiders that own Allergan stock include Brent L Saunders, Chris W Bodine, Christopher J Coughlin, Joseph H Boccuzi, Maria Teresa Hilado, Matthew M Walsh and William Meury. View Institutional Ownership Trends for Allergan.

AGN stock was sold by a variety of institutional investors in the last quarter, including Diamond Hill Capital Management Inc., State of New Jersey Common Pension Fund D, Robeco Institutional Asset Management B.V., Metropolis Capital Ltd, Russell Investments Group Ltd., Great West Life Assurance Co. Can, Envestnet Asset Management Inc. and Janney Capital Management LLC. View Insider Buying and Selling for Allergan.

AGN stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Tibra Equities Europe Ltd, California Public Employees Retirement System, Zweig DiMenna Associates LLC, GABELLI & Co INVESTMENT ADVISERS INC., FNY Investment Advisers LLC, ARP Americas LP and Gabelli Funds LLC. Company insiders that have bought Allergan stock in the last two years include Brent L Saunders, Chris W Bodine, Christopher J Coughlin, Joseph H Boccuzi, Maria Teresa Hilado and Matthew M Walsh. View Insider Buying and Selling for Allergan.

Shares of AGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AGN stock can currently be purchased for approximately $184.96.

Allergan has a market capitalization of $60.72 billion and generates $15.79 billion in revenue each year. The company earns $-5,096,400,000.00 in net income (profit) each year or $16.69 on an earnings per share basis. Allergan employs 16,900 workers across the globe.View Additional Information About Allergan.

The official website for Allergan is http://www.allergan.com/.

Allergan's mailing address is CLONSHAUGH BUSINESS AND TECHNOLOGY PARK COOLOCK, DUBLIN L2, D17 E400. The company can be reached via phone at 862-261-7000 or via email at [email protected]